NACE 21.20 in FR. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for G2D PHARMA combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
G2D PHARMA, a business in NACE sector 21.20, is registered at an address in France. The company was founded in 2013, incorporated as a 5710.
G2D PHARMA is listed in French National Business Register (RNE/INPI) under registry number 789754454. The public employee band is 02, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 21.20 band file annual accounts with INPI.
Across the 2017-2024 window revenue has declined, moving from €1,098,795 to €155,306.
An indicative valuation band is available for G2D PHARMA, based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2024 (period end 2024-12-31).
The data on this page is a public, point-in-time projection of G2D PHARMA's regulator-filed footprint, built to support indicative valuation bands, sellability context, and acquisition research.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €155,306 | - | €272,626 | €140,465 | - |
| 202331 Dec 2023 | - | - | €481,677 | €211,499 | - |
| 202231 Dec 2022 | - | - | €890,688 | €229,621 | - |
| 202131 Dec 2021 | €1,683,220 | - | €918,869 | €264,702 |
G2D PHARMA was founded in 2013 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
G2D PHARMA is registered under NACE 21.20: NACE 21.20. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for G2D PHARMA may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
| - |
| 202031 Dec 2020 | €1,252,027 | - | €1,135,839 | €205,638 | - |
| 201931 Dec 2019 | €1,052,967 | - | €1,015,492 | €151,286 | - |
| 201831 Dec 2018 | €1,022,240 | - | €840,744 | €137,745 | - |
| 201731 Dec 2017 | €1,098,795 | - | €922,150 | €113,206 | - |
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
